Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Gastric Cancer (CYTO-CHIP)

Civil Hospices of Lyon

Status: Completed

Conditions: Gastric Cancer; Peritoneal Carcinomatosis

Treatments: Procedure: Cytoreductive surgery alone; Procedure: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure

Study type: Observational

Funder types: Other

Identifiers

NCT03253939

CYTO-CHIP

Details and patient eligibility

About

Gastric cancer associated peritoneal carcinomatosis has a poor prognosis with a median survival of less than one year. Systemic chemotherapy including targeted agents has not been found to significantly increase the survival in Gastric cancer associated peritoneal carcinomatosis. Since recurrent gastric cancer remains confined to the abdominal cavity in many patients, regional therapies like aggressive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy have been investigated for Gastric cancer associated peritoneal carcinomatosis. Hyperthermic intraperitoneal chemotherapy has been used for three indications in Gastric Cancer- as an adjuvant therapy after a curative surgery, hyperthermic intraperitoneal chemotherapy has been shown to improve survival and reduce peritoneal recurrences in many randomised trials in Asian countries; as a definitive treatment in established PC, hyperthermic intraperitoneal chemotherapy along with cytoreductive surgery is the only therapeutic modality that has resulted in long-term survival in select groups of patients. While the results of randomised trials of adjuvant hyperthermic intraperitoneal chemotherapy from western centres are awaited, the role of hyperthermic intraperitoneal chemotherapy in the treatment of Gastric cancer associated peritoneal carcinomatosis is still evolving and needs larger studies before it is accepted as a standard of care.

Enrollment: 275 patients

Sex: All

Ages: 18 to 95 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed peritoneal carcinomatosis from gastric cancer
• Metachronous/synchronous peritoneal carcinomatosis

Exclusion criteria

• Gastric origin of peritoneal carcinomatosis unconfirmed

Trial design

275 participants in 2 patient groups

Case group

Description:

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure

Treatment:

Procedure: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure

Control group

Description:

Cytoreductive surgery alone

Treatment:

Procedure: Cytoreductive surgery alone